Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T, Janes J, Sun L, Chen S, Silverberg JI. Reich K, et al. Among authors: abe m. Br J Dermatol. 2023 Feb 10;188(2):208-217. doi: 10.1093/bjd/ljac057. Br J Dermatol. 2023. PMID: 36763879 Clinical Trial.
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H; ERASURE Study Japanese subgroup. Ohtsuki M, et al. Among authors: abe m. J Dermatol. 2014 Dec;41(12):1039-46. doi: 10.1111/1346-8138.12668. Epub 2014 Oct 30. J Dermatol. 2014. PMID: 25354738 Clinical Trial.
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
Abe M, Nishigori C, Torii H, Ihn H, Ito K, Nagaoka M, Isogawa N, Kawaguchi I, Tomochika Y, Kobayashi M, Tallman AM, Papp KA. Abe M, et al. J Dermatol. 2017 Nov;44(11):1228-1237. doi: 10.1111/1346-8138.13956. Epub 2017 Jul 17. J Dermatol. 2017. PMID: 28714180 Free PMC article. Clinical Trial.
Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.
Iozumi K, Abe M, Ito Y, Uesugi T, Onoduka T, Kato I, Kato F, Kodama K, Takahashi H, Takeda O, Tomizawa K, Nomiyama T, Fujii M, Mayama J, Muramoto F, Yasuda H, Yamanaka K, Sato T, Oh-I T, Kasai H, Tsuboi R, Hattori N, Maruyama R, Omi T, Shimoyama H, Sei Y, Nakasu I, Nishimoto S, Hata Y, Mochizuki T, Fukuzawa M, Seishima M, Sugiura K, Katayama I, Yamamoto O, Shindo M, Kiryu H, Kusuhara M, Takenaka M, Watanabe S. Iozumi K, et al. Among authors: abe m. J Dermatol. 2019 Aug;46(8):641-651. doi: 10.1111/1346-8138.14935. Epub 2019 Jun 17. J Dermatol. 2019. PMID: 31206779 Free PMC article. Clinical Trial.
English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors in the treatments of atopic dermatitis.
Saeki H, Akiyama M, Abe M, Igarashi A, Imafuku S, Ohya Y, Katoh N, Kameda H, Kabashima K, Tsunemi Y, Hide M, Ohtsuki M; Committee for reviewing the Safety of Atopic Dermatitis/Urticaria Treatment, Japanese Dermatological Association. Saeki H, et al. Among authors: abe m. J Dermatol. 2023 Jan;50(1):e1-e19. doi: 10.1111/1346-8138.16635. Epub 2022 Nov 22. J Dermatol. 2023. PMID: 36412059
6,231 results